Related references
Note: Only part of the references are listed.GLP-1 mimetics and cognition
Habib Yaribeygi et al.
LIFE SCIENCES (2021)
Could cilostazol be beneficial in COVID-19 treatment? Thinking about phosphodiesterase-3 as a therapeutic target
Nadia Alice Vieira Motta et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2021)
Traumatic Brain Injury Broadly Affects GABAergic Signaling in Dentate Gyrus Granule Cells
Alejandro Parga Becerra et al.
ENEURO (2021)
Aducanumab produced a clinically meaningful benefit in association with amyloid lowering
Jeffrey Cummings et al.
ALZHEIMERS RESEARCH & THERAPY (2021)
Liraglutide Protects Against Brain Amyloid-beta(1-42) Accumulation in Female Mice with Early Alzheimer's Disease-Like Pathology by Partially Rescuing Oxidative/Nitrosative Stress and Inflammation
Ana I. Duarte et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Mixed dementia: Neglected clinical entity or nosographic artifice?
Fabio Fierini
JOURNAL OF THE NEUROLOGICAL SCIENCES (2020)
Double blind, two dose, randomized, placebo-controlled, cross-over clinical trial of the positive allosteric modulator at the alpha7 nicotinic cholinergic receptor AVL-3288 in schizophrenia patients
Joshua T. Kantrowitz et al.
NEUROPSYCHOPHARMACOLOGY (2020)
Is that schizophrenia or frontotemporal dementia? Supporting clinicians in making the right diagnosis
Gabriele Cipriani et al.
ACTA NEUROLOGICA BELGICA (2020)
Cerebral microvascular complications of type 2 diabetes: stroke, cognitive dysfunction, and depression
Thomas T. van Sloten et al.
LANCET DIABETES & ENDOCRINOLOGY (2020)
A comprehensive description of GluN2B-selective N-methyl-D-aspartate (NMDA) receptor antagonists
Wenwu Liu et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
A Review on Tramiprosate (Homotaurine) in Alzheimer's Disease and Other Neurocognitive Disorders
Sagrario Manzano et al.
FRONTIERS IN NEUROLOGY (2020)
The impact and mechanism of ampakine CX1739 on protection against respiratory depression in rats
Dian Xiao et al.
FUTURE MEDICINAL CHEMISTRY (2020)
Cilostazol for Secondary Prevention of Stroke and Cognitive Decline Systematic Review and Meta-Analysis
Caroline McHutchison et al.
STROKE (2020)
Aducanumab, gantenerumab, BAN2401, and ALZ-801-the first wave of amyloid-targeting drugs for Alzheimer's disease with potential for near term approval
Martin Tolar et al.
ALZHEIMERS RESEARCH & THERAPY (2020)
Global prevalence and burden of HIV-associated neurocognitive disorder A meta-analysis
Yunhe Wang et al.
NEUROLOGY (2020)
Dual-acting agents for improving cognition and real-world function in Alzheimer's disease: Focus on 5-HT6 and D3 receptors as hubs
Mark J. Millan et al.
NEUROPHARMACOLOGY (2020)
Brexpiprazole for the Treatment of Schizophrenia in Adults: An Overview of Its Clinical Efficacy and Safety and a Psychiatrist's Perspective
Yoshinori Watanabe et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2020)
Randomized, Double-Blind, Placebo-Controlled Trial of the mGlu2/3 Negative Allosteric Modulator Decoglurant in Partially Refractory Major Depressive Disorder
Daniel Umbricht et al.
JOURNAL OF CLINICAL PSYCHIATRY (2020)
Dementia Risk in Type 2 Diabetes Patients: Acarbose Use and Its Joint Effects with Metformin and Pioglitazone
Chin-Hsiao Tseng
AGING AND DISEASE (2020)
The characteristics of cognitive neuroscience tests in a schizophrenia cognition clinical trial: Psychometric properties and correlations with standard measures
Michael S. Kraus et al.
SCHIZOPHRENIA RESEARCH-COGNITION (2020)
A precision medicine framework using artificial intelligence for the identification and confirmation of genomic biomarkers of response to an Alzheimer's disease therapy: Analysis of the blarcamesine (ANAVEX2-73) Phase 2a clinical study
Harald Hampel et al.
ALZHEIMERS & DEMENTIA-TRANSLATIONAL RESEARCH & CLINICAL INTERVENTIONS (2020)
Rasagiline monotherapy in early Parkinson's disease: A phase 3, randomized study in Japan
Nobutaka Hattori et al.
PARKINSONISM & RELATED DISORDERS (2019)
Emerging molecular mechanisms of vascular dementia
Milagros C. Romay et al.
CURRENT OPINION IN HEMATOLOGY (2019)
Brexpiprazole: A Review in Schizophrenia
James E. Frampton
DRUGS (2019)
Efficacy of Cilostazol Administration in Alzheimer's Disease Patients with White Matter Lesions: A Positron-Emission Tomography Study
Jun-Young Lee et al.
NEUROTHERAPEUTICS (2019)
Scn2a haploinsufficient mice display a spectrum of phenotypes affecting anxiety, sociability, memory flexibility and ampakine CX516 rescues their hyperactivity
Tetsuya Tatsukawa et al.
MOLECULAR AUTISM (2019)
Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer's disease: study protocol for a randomised controlled trial (ELAD study)
Grazia Daniela Femminella et al.
TRIALS (2019)
Blood amyloid levels and risk of dementia in the Ginkgo Evaluation of Memory Study (GEMS): A longitudinal analysis
Oscar L. Lopez et al.
ALZHEIMERS & DEMENTIA (2019)
Olfactory Dysfunction Mediates Adiposity in Cognitive Impairment of Type 2 Diabetes: Insights From Clinical and Functional Neuroimaging Studies
Zhou Zhang et al.
DIABETES CARE (2019)
Vascular Cognitive Impairment and Dementia
Costantino Iadecola et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
Antineuroinflammatory drugs in HIV-associated neurocognitive disorders as potential therapy
Bjoern Ambrosius et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2019)
Exenatide alleviates mitochondrial dysfunction and cognitive impairment in the 5 x FAD mouse model of Alzheimer's disease
Jingjing An et al.
BEHAVIOURAL BRAIN RESEARCH (2019)
Fluoxetine mitigating late-stage cognition and neurobehavior impairment induced by cerebral ischemia reperfusion injury through inhibiting ERS-mediated neurons apoptosis in the hippocampus
Feng Xu et al.
BEHAVIOURAL BRAIN RESEARCH (2019)
A Pilot Study of Exenatide Actions in Alzheimer's Disease
Roger J. Mullins et al.
CURRENT ALZHEIMER RESEARCH (2019)
Low-dose ladostigil for mild cognitive impairment A phase 2 placebo-controlled clinical trial
Lon S. Schneider et al.
NEUROLOGY (2019)
Understanding Frontotemporal Disease Progression and Management Strategies
Malissa Mulkey
NURSING CLINICS OF NORTH AMERICA (2019)
A Proof-of-Concept Study Evaluating the Phosphodiesterase 10A Inhibitor PF-02545920 in the Adjunctive Treatment of Suboptimally Controlled Symptoms of Schizophrenia
Nicholas DeMartinis et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2019)
The therapeutic effect of quetiapine on cognitive impairment associated with 5-HT1A presynaptic receptor involved schizophrenia
Dai Han et al.
JOURNAL OF INTEGRATIVE NEUROSCIENCE (2019)
Phosphodiesterase 10A Inhibitor Monotherapy Is Not an Effective Treatment of Acute Schizophrenia
David P. Walling et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2019)
ADX-47273, a mGlu5 receptor positive allosteric modulator, attenuates deficits in cognitive flexibility induced by withdrawal from 'binge-like' ethanol exposure in rats
Marta Marszalek-Grabska et al.
BEHAVIOURAL BRAIN RESEARCH (2018)
Dose-Related Target Occupancy and Effects on Circuitry, Behavior, and Neuroplasticity of the Glycine Transporter-1 Inhibitor PF-03463275 in Healthy and Schizophrenia Subjects
Deepak Cyril D'Souza et al.
BIOLOGICAL PSYCHIATRY (2018)
Alterations in Mesoscopic Oscillations affecting Episodic Memory following Developmental Traumatic Brain Injury
Chaitali Biswas et al.
EXPERIMENTAL NEUROLOGY (2018)
Effect of Idalopirdine as Adjunct to Cholinesterase Inhibitors on Change in Cognition in Patients With Alzheimer Disease Three Randomized Clinical Trials
Alireza Atri et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)
Revolution of Alzheimer Precision Neurology. Passageway of Systems Biology and Neurophysiology
Harald Hampel et al.
JOURNAL OF ALZHEIMERS DISEASE (2018)
Phase IIb Trial of an α7 Nicotinic Receptor Partial Agonist With and Without Nicotine Patch for Withdrawal-Associated Cognitive Deficits and Tobacco Abstinence
Randi Melissa Schuster et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2018)
Alpha7 nicotinic acetylcholine receptor-specific agonist DMXBA (GTS-21) attenuates Aβ accumulation through suppression of neuronal γ-secretase activity and promotion of microglial amyloid-β phagocytosis and ameliorates cognitive impairment in a mouse model of Alzheimer's disease
Kazuyuki Takata et al.
NEUROBIOLOGY OF AGING (2018)
Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease
Lawrence S. Honig et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Recent updates on GLP-1 agonists: Current advancements & challenges
Dilip Sharma et al.
BIOMEDICINE & PHARMACOTHERAPY (2018)
Diabetes, Depression, and Cognition: a Recursive Cycle of Cognitive Dysfunction and Glycemic Dysregulation
Sheila Black et al.
CURRENT DIABETES REPORTS (2018)
Long-Term Antipsychotic Effectiveness in First Episode of Psychosis: A 3-Year Follow-Up Randomized Clinical Trial Comparing Aripiprazole, Quetiapine, and Ziprasidone
Marcos Gomez-Revuelta et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2018)
Evaluation of Metformin on Cognitive Improvement in Patients With Non-dementia Vascular Cognitive Impairment and Abnormal Glucose Metabolism
Yufeng Lin et al.
FRONTIERS IN AGING NEUROSCIENCE (2018)
Pioglitazone Reduces Dementia Risk in Patients with Type 2 Diabetes Mellitus: A Retrospective Cohort Analysis
Chin-Hsiao Tseng
JOURNAL OF CLINICAL MEDICINE (2018)
Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimer's disease: results of a randomized, double-blind, placebo-controlled phase 2a study
Philip Scheltens et al.
ALZHEIMERS RESEARCH & THERAPY (2018)
12-month effects of incretins versus SGLT2-Inhibitors on cognitive performance and metabolic profile. A randomized clinical trial in the elderly with Type-2 diabetes mellitus
Simone Perna et al.
CLINICAL PHARMACOLOGY-ADVANCES AND APPLICATIONS (2018)
A randomized, double-blind, placebo-controlled crossover study of the effects of levetiracetam on cognition, mood, and balance in healthy older adults
Mike R. Schoenberg et al.
EPILEPSIA (2017)
Investigational phosphodiesterase inhibitors in phase I and phase II clinical trials for Alzheimer's disease
Jos Prickaerts et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2017)
Liraglutide promotes improvements in objective measures of cognitive dysfunction in individuals with mood disorders: A pilot, open-label study
Rodrigo B. Mansur et al.
JOURNAL OF AFFECTIVE DISORDERS (2017)
What is the Relationship of Traumatic Brain Injury to Dementia?
Mario F. Mendez
JOURNAL OF ALZHEIMERS DISEASE (2017)
Effects of pioglitazone on the incidence of dementia in patients with diabetes
Ping-Song Chou et al.
JOURNAL OF DIABETES AND ITS COMPLICATIONS (2017)
Further characterization of the GlyT-1 inhibitor Org25935: anti-alcohol, neurobehavioral, and gene expression effects
Helga Hoifodt Lido et al.
JOURNAL OF NEURAL TRANSMISSION (2017)
HIV-1-associated neurocognitive disorder: epidemiology, pathogenesis, diagnosis, and treatment
Christian Eggers et al.
JOURNAL OF NEUROLOGY (2017)
Efficacy and safety of the glycine transporter type-1 inhibitor AMG 747 for the treatment of negative symptoms associated with schizophrenia
Eduardo Dunayevich et al.
SCHIZOPHRENIA RESEARCH (2017)
BMS-933043, a Selective α7 nAChR Partial Agonist for the Treatment of Cognitive Deficits Associated with Schizophrenia
Dalton King et al.
ACS MEDICINAL CHEMISTRY LETTERS (2017)
Two decades of new drug discovery and development for Alzheimer's disease
Zhidong Liu et al.
RSC ADVANCES (2017)
Pathophysiology and Treatment of Memory Dysfunction After Traumatic Brain Injury
Rosalia Paterno et al.
CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS (2017)
Efficacy and safety of Ginkgo biloba standardized extract in the treatment of vascular cognitive impairment: a randomized, double-blind, placebo-controlled clinical trial
Vida Demarin et al.
NEUROPSYCHIATRIC DISEASE AND TREATMENT (2017)
Efficacy of rasagiline for the treatment of Parkinson's disease: an updated meta-analysis
Ying Chang et al.
ANNALS OF MEDICINE (2017)
Phase 2 Trial of an Alpha-7 Nicotinic Receptor Agonist (TC-5619) in Negative and Cognitive Symptoms of Schizophrenia
David Walling et al.
SCHIZOPHRENIA BULLETIN (2016)
Protection by sigma-1 receptor agonists is synergic with donepezil, but not with memantine, in a mouse model of amyloid-induced memory impairments
Tangui Maurice
BEHAVIOURAL BRAIN RESEARCH (2016)
Alzheimer's Disease: Targeting the Cholinergic System
Talita H. Ferreira-Vieira et al.
CURRENT NEUROPHARMACOLOGY (2016)
Tau Biology and Tau-Directed Therapies for Alzheimer's Disease
Lidia Bakota et al.
DRUGS (2016)
EGb761 improves cognitive function and regulates inflammatory responses in the APP/PS1 mouse
Wenbin Wan et al.
EXPERIMENTAL GERONTOLOGY (2016)
AVN-101: A Multi-Target Drug Candidate for the Treatment of CNS Disorders
Alexandre V. Ivachtchenko et al.
JOURNAL OF ALZHEIMERS DISEASE (2016)
Differential Susceptibility of Cortical and Subcortical Inhibitory Neurons and Astrocytes in the Long Term Following Diffuse Traumatic Brain Injury
Simone F. Carron et al.
JOURNAL OF COMPARATIVE NEUROLOGY (2016)
Therapy and clinical trials in frontotemporal dementia: past, present, and future
Richard M. Tsai et al.
JOURNAL OF NEUROCHEMISTRY (2016)
Rasagiline for mild cognitive impairment in Parkinson's disease: A placebo-controlled trial
Daniel Weintraub et al.
MOVEMENT DISORDERS (2016)
Varenicline Effects on Smoking, Cognition, and Psychiatric Symptoms in Schizophrenia: A Double-Blind Randomized Trial
Robert C. Smith et al.
PLOS ONE (2016)
Efficacy and safety of an adjunctive mGlu2 receptor positive allosteric modulator to a SSRI/SNRI in anxious depression
Justine M. Kent et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2016)
AZD8529, a positive allosteric modulator at the mGluR2 receptor, does not improve symptoms in schizophrenia: A proof of principle study
Robert E. Litman et al.
SCHIZOPHRENIA RESEARCH (2016)
Mavoglurant in fragile X syndrome: Results of two randomized, double-blind, placebo-controlled trials
Elizabeth Berry-Kravis et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
Editorial: Intellectual Disabilities in Down Syndrome from Birth and Throughout Life: Assessment and Treatment
Marie-Claude Potier et al.
FRONTIERS IN BEHAVIORAL NEUROSCIENCE (2016)
Altered Effective Connectivity of Hippocampus-Dependent Episodic Memory Network in mTBI Survivors
Hao Yan et al.
NEURAL PLASTICITY (2016)
In Vivo Characterization of ARN14140, a Memantine/Galantamine-Based Multi-Target Compound for Alzheimer's Disease
Angelo M. Reggiani et al.
SCIENTIFIC REPORTS (2016)
Adaptive, Dose-finding Phase 2 Trial Evaluating the Safety and Efficacy of ABT-089 in Mild to Moderate Alzheimer Disease
Robert A. Lenz et al.
ALZHEIMER DISEASE & ASSOCIATED DISORDERS (2015)
Follow-up evaluation of cognitive function in the randomized Alzheimer's Disease Anti-inflammatory Prevention Trial and its Follow-up Study
John Breitner et al.
ALZHEIMERS & DEMENTIA (2015)
AQW051, a novel, potent and selective α7 nicotinic ACh receptor partial agonist: pharmacological characterization and phase I evaluation
Dominik Feuerbach et al.
BRITISH JOURNAL OF PHARMACOLOGY (2015)
New Pharmacotherapy Targeting Cognitive Dysfunction of Schizophrenia via Modulation of GABA Neuronal Function
Takashi Uehara et al.
CURRENT NEUROPHARMACOLOGY (2015)
Randomized Proof of Concept Trial of GLYX-13, an N-Methyl-D-Aspartate Receptor Glycine Site Partial Agonist, in Major Depressive Disorder Nonresponsive to a Previous Antidepressant Agent
Sheldon Preskorn et al.
JOURNAL OF PSYCHIATRIC PRACTICE (2015)
Raloxifene for women with Alzheimer disease A randomized controlled pilot trial
Victor W. Henderson et al.
NEUROLOGY (2015)
Etanercept in Alzheimer disease: A randomized, placebo-controlled, double-blind, phase 2 trial
Joseph Butchart et al.
NEUROLOGY (2015)
Randomized, Double-Blind, Placebo-Controlled Study of Encenicline, an α7 Nicotinic Acetylcholine Receptor Agonist, as a Treatment for Cognitive Impairment in Schizophrenia
Richard S. E. Keefe et al.
NEUROPSYCHOPHARMACOLOGY (2015)
CHF5074 (CSP-1103) INDUCES MICROGLIA ALTERNATIVE ACTIVATION IN PLAQUE-FREE TG2576 MICE AND PRIMARY GLIAL CULTURES EXPOSED TO BETA-AMYLOID
V. Porrini et al.
NEUROSCIENCE (2015)
SELECTIVE ACTIVATION OF α7 NICOTINIC ACETYLCHOLINE RECEPTOR BY PHA-543613 IMPROVES Aβ25-35-MEDIATED COGNITIVE DEFICITS IN MICE
S. Sadigh-Eteghad et al.
NEUROSCIENCE (2015)
Targeting Prodromal Alzheimer Disease With Avagacestat A Randomized Clinical Trial
Vladimir Coric et al.
JAMA NEUROLOGY (2015)
Valproic Acid Alleviates Memory Deficits and Attenuates Amyloid-β Deposition in Transgenic Mouse Model of Alzheimer's Disease
Ai-Guo Xuan et al.
MOLECULAR NEUROBIOLOGY (2015)
Effects of the D-1 Dopamine Receptor Agonist Dihydrexidine (DAR-0100A) on Working Memory in Schizotypal Personality Disorder
Daniel R. Rosell et al.
NEUROPSYCHOPHARMACOLOGY (2015)
First Administration of the Fc-Attenuated Anti-β Amyloid Antibody GSK933776 to Patients with Mild Alzheimer's Disease: A Randomized, Placebo-Controlled Study
Niels Andreasen et al.
PLOS ONE (2015)
Clinical efficacy of lamotrigine and changes in the dosages of concomitantly used psychotropic drugs in Alzheimer's disease with behavioural and psychological symptoms of dementia: a preliminary open-label trial
Hidenobu Suzuki et al.
PSYCHOGERIATRICS (2015)
Cognitive decline reversed by cinacalcet
H. J. Wallace et al.
QJM-AN INTERNATIONAL JOURNAL OF MEDICINE (2015)
A Phase II Trial of Tideglusib in Alzheimer's Disease
Simon Lovestone et al.
JOURNAL OF ALZHEIMERS DISEASE (2015)
Effects of the Acetylcholine Release Agent ST101 with Donepezil in Alzheimer's Disease: A Randomized Phase 2 Study
Serge Gauthier et al.
JOURNAL OF ALZHEIMERS DISEASE (2015)
Cognitive Effects of Soy Isoflavones in Patients with Alzheimer's Disease
Carey E. Gleason et al.
JOURNAL OF ALZHEIMERS DISEASE (2015)
α7 Nicotinic Receptor Agonist Enhances Cognition in Aged 3xTg-AD Mice with Robust Plaques and Tangles
Rodrigo Medeiros et al.
AMERICAN JOURNAL OF PATHOLOGY (2014)
Valproic Acid Reduces Neuritic Plaque Formation and Improves Learning Deficits in APPSwe/PS1A246E Transgenic Mice via Preventing the Prenatal Hypoxia-Induced Down-Regulation of Neprilysin
Zheng Wang et al.
CNS NEUROSCIENCE & THERAPEUTICS (2014)
CHF5074 Protects SH-SY5Y Human Neuronal-like Cells from Amyloid-beta 25-35 and Tumor Necrosis Factor Related Apoptosis Inducing Ligand Toxicity In Vitro
Nicole Ronsisvalle et al.
CURRENT ALZHEIMER RESEARCH (2014)
A Multicenter, Double-Blind, Placebo-Controlled Trial of the PDE9A Inhibitor, PF-04447943, in Alzheimer's Disease
Elias M. Schwam et al.
CURRENT ALZHEIMER RESEARCH (2014)
The Selective Glycine Uptake Inhibitor Org 25935 as an Adjunctive Treatment to Atypical Antipsychotics in Predominant Persistent Negative Symptoms of Schizophrenia Results From the GIANT Trial
Joep H. Schoemaker et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2014)
Mild cognitive impairment: a concept in evolution
R. C. Petersen et al.
JOURNAL OF INTERNAL MEDICINE (2014)
Depression and dementia: Cause, consequence or coincidence?
Sophia Bennett et al.
MATURITAS (2014)
IN VIVO PHARMACOLOGICAL CHARACTERIZATION OF AC-3933, A BENZODIAZEPINE RECEPTOR PARTIAL INVERSE AGONIST FOR THE TREATMENT OF ALZHEIMER'S DISEASE
Y. Hatayama et al.
NEUROSCIENCE (2014)
A randomized, double-blind, placebo-controlled crossover study of α4β2* nicotinic acetylcholine receptor agonist AZD1446 (TC-6683) in adults with attention-deficit/hyperactivity disorder
Aurelija Jucaite et al.
PSYCHOPHARMACOLOGY (2014)
Efficacy and safety of aripiprazole in Chinese Han schizophrenia subjects: A randomized, double-blind, active parallel-controlled, multicenter clinical trial
Huafang Li et al.
SCHIZOPHRENIA RESEARCH (2014)
Structural analysis of the positive AMPA receptor modulators CX516 and Me-CX516 in complex with the GluA2 ligand-binding domain
Christian Krintel et al.
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY (2013)
CHF5074 Reduces Biomarkers of Neuroinflammation in Patients with Mild Cognitive Impairment: A 12-Week, Double-Blind, Placebo-Controlled Study
Joel Ross et al.
CURRENT ALZHEIMER RESEARCH (2013)
The potent M1 receptor allosteric agonist GSK1034702 improves episodic memory in humans in the nicotine abstinence model of cognitive dysfunction
Pradeep J. Nathan et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2013)
Mibampator (LY451395) randomized clinical trial for agitation/aggression in Alzheimer's disease
Paula T. Trzepacz et al.
INTERNATIONAL PSYCHOGERIATRICS (2013)
The Relationship Between Schizophrenia and Frontotemporal Dementia
Joseph J. Cooper et al.
JOURNAL OF GERIATRIC PSYCHIATRY AND NEUROLOGY (2013)
Thirty years beyond discovery-Clinical trials in succinic semialdehyde dehydrogenase deficiency, a disorder of GABA metabolism
Kara R. Vogel et al.
JOURNAL OF INHERITED METABOLIC DISEASE (2013)
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of α4β2 Agonist ABT-894 in Adults with ADHD
Earle E. Bain et al.
NEUROPSYCHOPHARMACOLOGY (2013)
The AMPA receptor modulator S18986 in the prelimbic cortex enhances acquisition and retention of an odor-reward association
Natalya Yefimenko et al.
NEUROSCIENCE LETTERS (2013)
The Amygdala Excitatory/Inhibitory Balance in a Valproate-Induced Rat Autism Model
Hui-Ching Lin et al.
PLOS ONE (2013)
Schizophrenia and frontotemporal dementia: Shared causation?
Michal Harciarek et al.
INTERNATIONAL REVIEW OF PSYCHIATRY (2013)
Effect of Immunotherapy With Bapineuzumab on Cerebrospinal Fluid Biomarker Levels in Patients With Mild to Moderate Alzheimer Disease
Kaj Blennow et al.
ARCHIVES OF NEUROLOGY (2012)
Pilot Randomized Controlled Study of a Histamine Receptor Inverse Agonist in the Symptomatic Treatment of AD
Michael Egan et al.
CURRENT ALZHEIMER RESEARCH (2012)
Efficacy of Souvenaid in Mild Alzheimer's Disease: Results from a Randomized, Controlled Trial
Philip Scheltens et al.
JOURNAL OF ALZHEIMERS DISEASE (2012)
Long-term use of standardised ginkgo biloba extract for the prevention of Alzheimer's disease (GuidAge): a randomised placebo-controlled trial
Bruno Vellas et al.
LANCET NEUROLOGY (2012)
Metformin attenuates Alzheimer's disease-like neuropathology in obese, leptin-resistant mice
Jiejie Li et al.
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR (2012)
Effects of D-cycloserine on MPTP-induced behavioral and neurological changes: Potential for treatment of Parkinson's disease dementia
Ying-Jui Ho et al.
BEHAVIOURAL BRAIN RESEARCH (2011)
A Randomized Clinical Trial of MK-0777 for the Treatment of Cognitive Impairments in People with Schizophrenia
Robert W. Buchanan et al.
BIOLOGICAL PSYCHIATRY (2011)
Rosiglitazone Does Not Improve Cognition or Global Function when Used as Adjunctive Therapy to AChE Inhibitors in Mild-to-Moderate Alzheimer's Disease: Two Phase 3 Studies
C. Harrington et al.
CURRENT ALZHEIMER RESEARCH (2011)
Curcumin activates Wnt/β-catenin signaling pathway through inhibiting the activity of GSK-3β in APPswe transfected SY5Y cells
Xiong Zhang et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2011)
Cotinine Reduces Amyloid-beta Aggregation and Improves Memory in Alzheimer's Disease Mice
Valentina Echeverria et al.
JOURNAL OF ALZHEIMERS DISEASE (2011)
The Cysteine Protease Inhibitor, E64d, Reduces Brain Amyloid-beta and Improves Memory Deficits in Alzheimer's Disease Animal Models by Inhibiting Cathepsin B, but not BACE1, beta-Secretase Activity
Gregory Hook et al.
JOURNAL OF ALZHEIMERS DISEASE (2011)
The memory-enhancing effects of Kami-ondam-tang in mice
Jin Gyu Hong et al.
JOURNAL OF ETHNOPHARMACOLOGY (2011)
Neuroprotective Effects of Citidine-5-diphosphocholine on Impaired Spatial Memory in a Rat Model of Cerebrovascular Dementia
Kotaro Takasaki et al.
JOURNAL OF PHARMACOLOGICAL SCIENCES (2011)
5-HT4 receptor agonist mediated enhancement of cognitive function in vivo and amyloid precursor protein processing in vitro: A pharmacodynamic and pharmacokinetic assessment
Fei Shen et al.
NEUROPHARMACOLOGY (2011)
Involvement of the Glycogen Synthase Kinase-3 Signaling Pathway in TBI Pathology and Neurocognitive Outcome
Pramod K. Dash et al.
PLOS ONE (2011)
Donepezil Impairs Memory in Healthy Older Subjects: Behavioural, EEG and Simultaneous EEG/fMRI Biomarkers
Joshua H. Balsters et al.
PLOS ONE (2011)
Drug targets for cognitive enhancement in neuropsychiatric disorders
Tanya L. Wallace et al.
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR (2011)
Activation of CREB by St. John's Wort May Diminish Deletorious Effects of Aging on Spatial Memory
Emil Trofimiuk et al.
ARCHIVES OF PHARMACAL RESEARCH (2010)
The N-Methyl-D-Aspartate Receptor Co-agonist D-Cycloserine Facilitates Declarative Learning and Hippocampal Activity in Humans
Oezguer A. Onur et al.
BIOLOGICAL PSYCHIATRY (2010)
Ultrastructural and transcriptional profiling of neuropathological misregulation of CREB function
L. M. Valor et al.
CELL DEATH AND DIFFERENTIATION (2010)
S 18986: A Positive Allosteric Modulator of AMPA-Type Glutamate Receptors Pharmacological Profile of a Novel Cognitive Enhancer
Katy Bernard et al.
CNS NEUROSCIENCE & THERAPEUTICS (2010)
Double-Blind, Controlled Phase II Study of a 5-HT6 Receptor Antagonist, SB-742457, in Alzheimer's Disease
G. Maher-Edwards et al.
CURRENT ALZHEIMER RESEARCH (2010)
Cognitive Improvement by Activation of alpha(7) Nicotinic Acetylcholine Receptors: From Animal Models to Human Pathophysiology
Morten S. Thomsen et al.
CURRENT PHARMACEUTICAL DESIGN (2010)
Luteolin promotes long-term potentiation and improves cognitive functions in chronic cerebral hypoperfused rats
Bei Xu et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2010)
HIV-Associated Neurocognitive Disorder: Pathogenesis and Therapeutic Opportunities
Kathryn A. Lindl et al.
JOURNAL OF NEUROIMMUNE PHARMACOLOGY (2010)
Activation of Wnt signaling by lithium and rosiglitazone reduced spatial memory impairment and neurodegeneration in brains of an APPswe/PSEN1ΔE9 mouse model of Alzheimer's disease
E. M. Toledo et al.
MOLECULAR PSYCHIATRY (2010)
The n-butanolic extract of Opuntia ficus-indica var. saboten enhances long-term memory in the passive avoidance task in mice
Jong Min Kim et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2010)
Targeting the correct HDAC(s) to treat cognitive disorders
Andre Fischer et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2010)
Vitamin E Protects Against Oxidative Damage and Learning Disability After Mild Traumatic Brain Injury in Rats
Aiguo Wu et al.
NEUROREHABILITATION AND NEURAL REPAIR (2010)
Exebryl-1: A novel small molecule currently in human clinical trials as a disease-modifying drug for the treatment of Alzheimer's disease
Alan D. Snow et al.
Alzheimers & Dementia (2009)
Curcumin-induced degradation of PKCδ is associated with enhanced dentate NCAM PSA expression and spatial learning in adult and aged Wistar rats
Lisa Conboy et al.
BIOCHEMICAL PHARMACOLOGY (2009)
Preclinical pharmacology of the α4β2 nAChR partial agonist varenicline related to effects on reward, mood and cognition
Hans Rollema et al.
BIOCHEMICAL PHARMACOLOGY (2009)
Exercise-induced improvement in cognitive performance after traumatic brain injury in rats is dependent on BDNF activation
Grace Sophia Griesbach et al.
BRAIN RESEARCH (2009)
Tanshinone I enhances learning and memory, and ameliorates memory impairment in mice via the extracellular signal-regulated kinase signalling pathway
Dong Hyun Kim et al.
BRITISH JOURNAL OF PHARMACOLOGY (2009)
17β-estradiol and enriched environment accelerate cognitive recovery after focal brain ischemia
Ingegerd Soderstrom et al.
EUROPEAN JOURNAL OF NEUROSCIENCE (2009)
Inhibition of poly(ADP-ribose) polymerase suppresses inflammation and promotes recovery after ischemic injury
Tiina M. Kauppinen et al.
JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM (2009)
A pilot open label, single dose trial of fenobam in adults with fragile X syndrome
E. Berry-Kravis et al.
JOURNAL OF MEDICAL GENETICS (2009)
The Novel Cholinesterase-Monoamine Oxidase Inhibitor and Antioxidant, Ladostigil, Confers Neuroprotection in Neuroblastoma Cells and Aged Rats
Orit Bar-Am et al.
JOURNAL OF MOLECULAR NEUROSCIENCE (2009)
Procognitive and Neuroprotective Activity of a Novel α7 Nicotinic Acetylcholine Receptor Agonist for Treatment of Neurodegenerative and Cognitive Disorders
Renza Roncarati et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2009)
Beneficial effects of quetiapine in a transgenic mouse model of Alzheimer's disease
Jue He et al.
NEUROBIOLOGY OF AGING (2009)
Protein kinase C activity is associated with prefrontal cortical decline in aging
Avis R. Brennan et al.
NEUROBIOLOGY OF AGING (2009)
mGluR5 Positive Allosteric Modulators Facilitate both Hippocampal LTP and LTD and Enhance Spatial Learning
Jennifer E. Ayala et al.
NEUROPSYCHOPHARMACOLOGY (2009)
Identification of compounds that potentiate CREB signaling as possible enhancers of long-term memory
Menghang Xia et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Initial phase 2 trial of a nicotinic agonist in schizophrenia
Robert Freedman et al.
AMERICAN JOURNAL OF PSYCHIATRY (2008)
Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia
Anantha Shekhar et al.
AMERICAN JOURNAL OF PSYCHIATRY (2008)
Memory enhancement induced by hypothalamic/fornix deep brain stimulation
Clement Hamani et al.
ANNALS OF NEUROLOGY (2008)
Selective dopamine D-4 receptor agonist (A-412997) improves cognitive performance and stimulates motor activity without influencing reward-related behaviour in rat
Marie L. Woolley et al.
BEHAVIOURAL PHARMACOLOGY (2008)
The role of GSK-3 in synaptic plasticity
S. Peineau et al.
BRITISH JOURNAL OF PHARMACOLOGY (2008)
Synergistic effects of chronic bryostatin-1 and α-tocopherol on spatial learning and memory in rats
Miao-Kun Sun et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2008)
Antidepressant drugs and memory: Insights from animal studies
Santiago Monleon et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2008)
CaM kinase II and protein kinase C activations mediate enhancement of long-term potentiation by nefiracetam in the rat hippocampal CA1 region
Shigeki Moriguchi et al.
JOURNAL OF NEUROCHEMISTRY (2008)
The role of the basal ganglia in data processing
James Leyden et al.
MEDICAL HYPOTHESES (2008)
Dementia and survival in Parkinson disease - A 12-year population study
T. C. Buter et al.
NEUROLOGY (2008)
D-JNKi, a peptide inhibitor of c-Jun N-terminal kinase, promotes functional recovery after transient focal cerebral ischemia in rats
E. Esneault et al.
NEUROSCIENCE (2008)
Pathophysiology of the basal ganglia and movement disorders: From animal models to human clinical applications
Zvi Israel et al.
NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS (2008)
A role for the 5-HT1A, 5-HT4 and 5-HT6 receptors in learning and memory
Madeleine V. King et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2008)
Modafinil: A review of neurochemical actions and effects on cognition
Michael J. Minzenberg et al.
NEUROPSYCHOPHARMACOLOGY (2008)
A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia
Donald C. Goff et al.
NEUROPSYCHOPHARMACOLOGY (2008)
Improvement of cognitive deficit and neuronal damage in rats with chronic cerebral ischemia via relative long-term inhibition of Rho-kinase
Lin Huang et al.
CELLULAR AND MOLECULAR NEUROBIOLOGY (2008)
Effect of ispronicline, a neuronal nicotinic acetylcholine receptor partial agonist, in subjects with age associated memory impairment (AAMI) (vol 21, pg 171, 2007)
Geoffrey C. Dunbar
JOURNAL OF PSYCHOPHARMACOLOGY (2008)
(-)-epigallocatechin gallate, the most active polyphenolic catechin in green tea, presynaptically facilitates Ca2+-Dependent glutamate release via activation of protein kinase C in rat cerebral cortex
Chien-Wen Chou et al.
SYNAPSE (2007)
Profile of cognitive impairment in dementia associated with Parkinson's disease compared with Alzheimer's disease
Kolbjorn Bronnick et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2007)
Broad-spectrum efficacy across cognitive domains by α7 nicotinic acetylcholine receptor agonism correlates with activation of ERK1/2 and CREB phosphorylation pathways
Robert S. Bitner et al.
JOURNAL OF NEUROSCIENCE (2007)
Evolution of cognitive dysfunction in an incident Parkinson's disease cohort
C. H. Williams-Gray et al.
BRAIN (2007)
Effects of TC-1734 (AZD3480), a selective neuronal nicotinic receptor agonist, on cognitive performance and the EEG of young healthy male volunteers
G. Dunbar et al.
PSYCHOPHARMACOLOGY (2007)
Effect of ispronicline, a neuronal nicotinic acetylcholine receptor partial agonist, in subjects with age associated memory impairment (AAMI)
Geoffrey C. Dunbar et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2007)
Neuroprotective effects of regulators of the glycogen synthase kinase-3β signaling pathway in a transgenic model of Alzheimer's disease are associated with reduced amyloid precursor protein phosphorylation
Edward Rockenstein et al.
JOURNAL OF NEUROSCIENCE (2007)
PKC signaling deficits: a mechanistic hypothesis for the origins of Alzheimer's disease
Daniel L. Alkon et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2007)
Rivastigmine and Parkinson dementia complex
Rita Moretti et al.
EXPERT OPINION ON PHARMACOTHERAPY (2007)
Phosphatidylserine and phosphatidylcholine-containing liposomes inhibit amyloid beta and interferon-gamma-induced microglial activation
Sadayuki Hashioka et al.
FREE RADICAL BIOLOGY AND MEDICINE (2007)
Chronic treatment with minocycline preserves adult new neurons and reduces functional impairment after focal cerebral ischemia
Zhengyan Liu et al.
STROKE (2007)
Immunotherapy against APP beta-secretase cleavage site improves cognitive function and reduces neuroinflammation in Tg2576 mice without a significant effect on brain A beta levels
Idan Rakover et al.
NEURODEGENERATIVE DISEASES (2007)
Advances in the treatment of Parkinson's disease
Neha Singh et al.
PROGRESS IN NEUROBIOLOGY (2007)
Lipoic acid as a novel treatment for Alzheimer's disease and related dementias
Lina Holmquist et al.
PHARMACOLOGY & THERAPEUTICS (2007)
Clinical phenotype of Parkinson disease dementia
James E. Galvin et al.
NEUROLOGY (2006)
Caffeine protects Alzheimer's mice against cognitive impairment and reduces brain β-amyloid production
G. W. Arendash et al.
NEUROSCIENCE (2006)
Glycogen synthase kinase-3 - An overview of an over-achieving protein kinase
Lisa Kockeritz et al.
CURRENT DRUG TARGETS (2006)
An inverse agonist selective for α5 subunit-containing GABAA receptors improves encoding and recall but not consolidation in the Morris water maze
N. Collinson et al.
PSYCHOPHARMACOLOGY (2006)
Enhancement of long-term spatial memory in adult rats by the noncompetitive NMDA receptor antagonists, memantine and neramexane
Phillip R. Zoladz et al.
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR (2006)
CREB activity maintains the survival of cingulate cortical pyramidal neurons in the adult mouse brain
Hushan Ao et al.
MOLECULAR PAIN (2006)
Procholinergic and memory enhancing properties of the selective norepinephrine uptake inhibitor atomoxetine
ET Tzavara et al.
MOLECULAR PSYCHIATRY (2006)
Cognitive deficits and psychosis in Parkinson's disease - A review of pathophysiology and therapeutic options
Caroline H. Williams-Gray et al.
CNS DRUGS (2006)
Management of Parkinson's disease dementia - Practical considerations
Arvid Rongve et al.
DRUGS & AGING (2006)
L-dopa impairs learning, but spares generalization, in Parkinson's disease
D Shohamy et al.
NEUROPSYCHOLOGIA (2006)
FK962, a novel enhancer of somatostatin release, exerts cognitive-enhancing actions in rats
K Tokita et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2005)
Lecozotan (SRA-333): A selective serotonin 1A receptor antagonist that enhances the stimulated release of glutamate and acetylcholine in the hippocampus and possesses cognitive-enhancing properties
LE Schechter et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2005)
Effects of histamine H3 receptor antagonists in two models of spatial learning
VA Komater et al.
BEHAVIOURAL BRAIN RESEARCH (2005)
The effect of Ondansetron on memory in schizophrenic patients
Y Levkovitz et al.
BRAIN RESEARCH BULLETIN (2005)
On the trail of a cognitive enhancer for the treatment of schizophrenia
E Stip et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2005)
PKC signaling mediates global enhancement of excitatory synaptogenesis in neurons triggered by local contact with astrocytes
H Hama et al.
NEURON (2004)
Mitochondrial dysfunction and oxidative damage in Alzheimer's and Parkinson's diseases and coenzyme Q10 as a potential treatment
MF Beal
JOURNAL OF BIOENERGETICS AND BIOMEMBRANES (2004)
Mixed dementia - Emerging. concepts and therapeutic implications
KM Langa et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2004)
Rivastigmine for dementia associated with Parkinson's disease
M Emre et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Mechanisms of action of cognitive enhancers on neuroreceptors
T Narahashi et al.
BIOLOGICAL & PHARMACEUTICAL BULLETIN (2004)
Alpha-7 nicotinic receptor agonists: potential new candidates for the treatment of schizophrenia
LF Martin et al.
PSYCHOPHARMACOLOGY (2004)
Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia
D Aarsland et al.
INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY (2003)
A comparative study in rodents of standardized extracts of Bacopa monniera and Ginkgo biloba -: Anticholinesterase and cognitive enhancing activities
A Das et al.
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR (2002)
Docosahexaenoic acid provides protection from impairment of learning ability in Alzheimer's disease model rats
M Hashimoto et al.
JOURNAL OF NEUROCHEMISTRY (2002)
Dopamine and the regulation of cognition and attention
A Nieoullon
PROGRESS IN NEUROBIOLOGY (2002)
Glucocorticoids interact with the basolateral amygdala β-adrenoceptor-cAMP/PKA system in influencing memory consolidation
B Roozendaal et al.
EUROPEAN JOURNAL OF NEUROSCIENCE (2002)
Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefit
E Giacobini et al.
JOURNAL OF NEURAL TRANSMISSION (2002)
Pathways to neuronal injury and apoptosis in HIV-associated dementia
M Kaul et al.
NATURE (2001)
The beneficial effect of cholinesterase inhibitors on patients suffering from Parkinson's disease and dementia
EA Werber et al.
JOURNAL OF NEURAL TRANSMISSION (2001)
The alpha-2A-adrenoceptor agonist, guanfacine, increases regional cerebral blood flow in dorsolateral prefrontal cortex of monkeys performing a spatial working memory task
RA Avery et al.
NEUROPSYCHOPHARMACOLOGY (2000)
Share Paper
